TEVA, US8816242098

Teva stock: Innovative brands lift 2026 revenue outlook

Published on 11/09/2026 at 17:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Teva stock enters the next phase of its growth plan as branded medicines gain momentum. Generic competition remains a drag on quarterly revenue.

Innovative brands reshape Teva's outlook

Teva's third-quarter revenue fell as generic-drug competition offset growth in key branded medicines.
Management raised its full-year revenue guidance and lifted forecasts for AUSTEDO, AJOVY and UZEDY.
Weltruza and the biosimilar pipeline add further growth options beyond 2026.

TEVA, US8816242098, Illustration mit AI erstellt.

Teva Pharmaceutical Industries reported mixed third-quarter results on Tuesday, November 3, 2026, but raised its full-year revenue outlook as growth in innovative medicines offset weaker generic-drug sales. In its Teva press release, the company said third-quarter revenue reached USD 4.395 billion, down 2 percent from a year earlier in both reported and local-currency terms.

Branded medicines drive guidance

AUSTEDO, AJOVY and UZEDY generated about USD 1.1 billion in combined revenue and grew 33 percent year over year in local currency. AUSTEDO revenue rose 21 percent to USD 751 million, AJOVY advanced 61 percent to USD 269 million and UZEDY climbed 96 percent to USD 85 million.

Teva lifted its 2026 revenue outlook to USD 16.7 billion to USD 17.0 billion from USD 16.5 billion to USD 16.85 billion. The company also raised its product forecasts to USD 2.55 billion to USD 2.65 billion for AUSTEDO, USD 930 million to USD 960 million for AJOVY and USD 290 million to USD 310 million for UZEDY.

Generic pressure remains visible

Global generic revenue declined 16 percent in local currency, chiefly because of lower U.S. sales of generic lenalidomide amid increased competition. Teva said biosimilar revenue is expected to exceed USD 0.8 billion in 2026, reaching its original 2027 target one year early.

GAAP diluted earnings per share fell to USD 0.20 from USD 0.37, while non-GAAP diluted earnings per share increased to USD 0.86 from USD 0.78. Teva attributed the adjusted improvement to stronger gross margins and growth in its innovative portfolio; the adjusted figure excludes items including impairments, legal settlements and financial expenses.

Pipeline adds longer-term options

The U.S. approval of Weltruza in October expands Teva's long-acting injectable schizophrenia portfolio alongside Uzedy. The company also highlighted its biosimilar collaboration with Samsung Bioepis, the acquisition of BXCL-501 and a potential 2027 regulatory decision for ecopipam.

For investors, the results underline the transition from generic-heavy revenue toward branded growth, while competition in generics and execution around new launches remain key variables for the raised outlook.

U.S. pharmaceutical stocks traded within the broader S&P 500 market environment.

More news and analyses on Teva stock